Effects of liraglutide on cardiovascular risk factors in patients with type 1 diabetes

摘要

We investigated the short-term effect of adding liraglutide 1.8 mg once daily to insulin treatment on cardiovascular risk factors in patients with type 1 diabetes. In total, 100 overweight (BMI >= 25 kg/m(2)) adult patients (age >= 18 years) with type 1 diabetes and HbA1c >= 8% (64 mmol/mol) were randomized to liraglutide 1.8 mg or placebo added to insulin treatment in a 24-week double-blinded, placebo-controlled trial. At baseline and after 24 weeks of treatment, 24-hour blood pressure and heart rate, pulse pressure, pulse wave velocity and carotid intima-media thickness were evaluated. Compared with placebo, liraglutide increased 24-hour heart rate by 4.6 beats per minute (BPM); P =.0015, daytime heart rate by 3.7; P =.0240 and night-time heart rate by 7.5 BPM; P <.001 after 24 weeks. Diastolic nocturnal blood pressure increased by 4 mm Hg; P =.0362 in the liraglutide group compared with placebo. In conclusion, in patients with long-standing type 1 diabetes, liraglutide as add-on to insulin increased heart rate and did not improve other cardiovascular risk factors after 24 weeks of treatment.